Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies.
Saved in:
| Title: | Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies. |
|---|---|
| Authors: | Bender Ignacio RA; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA.; Vaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, WA, USA., Chew KW; Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Moser C; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA., Currier JS; Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Eron JJ; Division of Infectious Diseases, Department of Medicine, University of Carolina School of Medicine, Chapel Hill, NC, USA., Javan AC; National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA., Giganti MJ; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA., Ritz J; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA., Gibbs M; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Kouekam HT; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Esser MT; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Daar ES; Division of HIV Medicine, Lundquist Institute, Harbor-UCLA Medical Center, Los Angeles, CA, USA., Choudhary M; Division of Infectious Diseases, Department of Medicine, Harvard Medical School, Boston, MA, USA., Deo R; Division of Infectious Diseases, Department of Medicine, Harvard Medical School, Boston, MA, USA., Fletcher CV; UNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha, NE, USA., Li JZ; Division of Infectious Diseases, Department of Medicine, Harvard Medical School, Boston, MA, USA., Hughes MD; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA., Smith D; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, CA, USA., Wohl DA; Division of Infectious Diseases, Department of Medicine, University of Carolina School of Medicine, Chapel Hill, NC, USA. |
| Corporate Authors: | ACTIV-2/A5401 Study Team |
| Source: | IScience [iScience] 2025 Feb 04; Vol. 28 (3), pp. 111938. Date of Electronic Publication: 2025 Feb 04 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Cell Press Country of Publication: United States NLM ID: 101724038 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-0042 (Electronic) Linking ISSN: 25890042 NLM ISO Abbreviation: iScience Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
